乐普医疗：注射用重组A型肉毒毒素获得药物临床试验批准通知书

Core Viewpoint - Lepu Medical (300003.SZ) announced that its subsidiary, Lepu Jiantang Pharmaceutical (Chongqing) Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its self-developed injectable recombinant type A botulinum toxin, indicating strong R&D capabilities in the dermatology field [2] Group 1 - The approved product has advantages such as low biological risk and high purity, enhancing the company's product portfolio in dermatology [2] - The development of this product is expected to strengthen the company's core competitiveness in the dermatology segment [2] - The project is still in the early stages of development, with high uncertainty regarding clinical trial outcomes, significant R&D investment, and long trial cycles [2]